No abstract

Now on the market in the United States for almost 3 years and available in 48 countries worldwide, solifenacin 5 mg or 10 mg once daily continues to demonstrate a profile of safety and efficacy as a treatment for incontinence, urgency, and other symptoms of OAB. More than 2.2 million patients have been treated worldwide with solifenacin. Safety and efficacy data across numerous studies in several thousand patients, along with flexible dosing, support the use of this agent as a first-line antimuscarinic treatment for OAB. Data from large randomized controlled trials such as VENUS and STAR show statistically significant superiority compared with placebo and improved outcomes over those achieved with tolterodine ER 4 mg. Solifenacin is an agent of choice for OAB-related incontinence, with more than 50% of incontinent patients reporting no incontinence episodes after 12 weeks of solifenacin therapy. In addition to improved efficacy, solifenacin offers good tolerability with a low incidence of side effects. Once-daily, flexible dosing with this agent provides 24-hour control of OAB symptoms and significantly increases warning time (the period from onset of urgency to voiding), which may also increase a patient's chance of avoiding episodes of incontinence.

No abstract

The shorter life span and poorer health of men compared with women is concerning, affecting spouses, families, and communities. Physicians and policy makers have identified a growing need for a gender-specific focus on the unique health needs of boys and men and accompanying services. Men's health has emerged as a new discipline that is responsible for a gender-specific approach to health-services delivery, government policy, research, and advocacy. The urologic community has taken a leadership role in this specialty by defining the issues that face men in the 21(st) century, bringing together disparate areas of clinical care and research, and collaborating with stakeholders (such as primary care physicians and specialists from other disciplines) to create and implement men's health initiatives.